CPT1A is the rate-limiting enzyme of mitochondrial β-oxidation, and it has been recognized as a potential therapeutic target for hepatocellular carcinoma (HCC) and ccRCC 3, 14. This evidence concerns the gene CPT1A and hepatocellular carcinoma.